Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1801 to 1815 of 1866 results for do not do

  1. New weekly treatment option approved for people with haemophilia B

    Our final draft guidance published today recommends marstacimab (also called Hympavzi and made by Pfizer) for treating the severe form of blood disorder haemophilia B in people 12 years and over.

  2. New guideline will help cut falls and related hospital admissions for older and at-risk people

    Personalised assessments that consider factors including the hazards in a person’s home, and their previous medical history will help reduce falls in older and at-risk people, according to a new NICE guideline.

  3. HST routing criteria: encouraging innovation in the treatment of ultra-rare diseases

    Our chief medical officer, Professor Jonathan Benger, explains the crucial role the HST programme plays in encouraging innovation in the treatment of ultra-rare diseases. He also highlights why effective routing is essential to getting the best care to patients across the NHS.

  4. Changes approved to the routing criteria for highly specialised technologies

    At its meeting on 19 March our Board approved changes to the criteria we use to decide which treatments should be evaluated, to ensure more consistent, predictable and transparent decisions.

  5. New drug approved for inherited clotting disorder, offering simpler dosing and enhanced quality of life.

    NICE publishes final draft guidance recommending efanesoctocog alfa as an option for treating and preventing bleeding in people aged 2 and over with severe haemophilia A.

  6. New life-changing treatment option recommended for type of rare epilepsy

    This marks a significant step forward for around 1,400 people living with this rare and severe form of epilepsy, which typically begins in early childhood.

  7. Planning for the International Recognition Procedure

    5 ways NICE Advice can help you navigate this new opportunity alongside health technology assessment.

  8. NICE recommends 8 digitally enabled therapies to treat depression and anxiety

    Eight digital enabled therapies to treat depression and anxiety disorders in adults have been conditionally recommended by NICE in draft guidance.

  9. Two technologies to provide digital services for people with COPD

    More people with chronic obstructive pulmonary disease (COPD) could soon access rehabilitation programmes after draft guidance from NICE conditionally recommended two technologies to provide digital services to NHS patients.

  10. Adults with depression who want to quit antidepressants should be given support

    Adults with depression who want to stop taking antidepressants should have the dose of their medication reduced in stages to reduce the likelihood and severity of withdrawal symptoms, NICE has said.

  11. NICE recommended personalised immunotherapy to treat blood cancer in children and young adults to be made routinely available on the NHS

    Innovative CAR-T therapy recommended to treat an aggressive form of leukaemia.

  12. Home testing devices could increase the number of people diagnosed with sleep apnoea

    Five home-testing devices to diagnose a silent sleep condition harming the health of an estimated 2.5 million adults have been recommended by NICE in draft guidance.

  13. NICE's Early Value Assessment for Medtech: panning for nuggets of innovation gold

    Early Value Assessment for Medtech and how it will offer a rapid assessment of digital products, devices and diagnostics for clinical effectiveness and value for money.

  14. Teaching the basics of health technology assessment

    NICE has launched a free learning course that provides an introduction to health technology assessment (HTA).

  15. Children and young people need accurate, accessible information about their healthcare

    New draft guidance from NICE recommends children and young people are fully informed about their health so that they can take an active role in their healthcare.